Reporting Requirements for Studies Involving Investigational Devices
Version Date: April 29, 2010
University of Wisconsin-Madison Health Sciences Institutional Review Boards Adverse Events Reporting Guidelines for Studies Involving Investigational Devices
FDA Regulations require the investigator on a device trial to report to the IRB (and the sponsor) any unanticipated adverse device effect occurring during an investigation of the device. [21 CFR 812.150(a)]. An “unanticipated adverse device effect” is defined as either:
- Any serious adverse effect on health or safety or any life-threatening problem or death, caused by or associated with the device, if that effect, problem or death was not previously identified in nature, severity or degree of incidence in the investigational plan or application (including a supplementary plan or application); OR
- Any other unanticipated serious problem associated with the device that relates to the rights, safety or welfare of subjects. [21 CFR 812.3(s)].
- Any adverse events involving devices that require immediate intervention to prevent serious harm to participants or others must be reported to the IRB chair or director within 1 business day of its discovery.
- All adverse events involving devices that occur in subjects under UW-Madison IRB purview who are enrolled in research studies that have been reviewed and approved by the Madison VA’s Research & Development Committee (i.e., fall under Madison VA purview) must be reported to the IRB and Associate Chief of Staff for Research regardless of their expected relationship to the study within 5 business days of the local research team becoming aware of the event.
- All other events must be reported to the IRB as soon as possible, but no later than 10 business days after the investigator first learns of any unanticipated adverse device effect occurring during the investigation.
45 CFR 46.103 (HHS) assuring compliance
21 CFR 56.108 (FDA) IRB functions and operations
21 CFR 312.32 (FDA) reporting requirement for sponsors
21 CFR 312.66 (FDA) reporting requirements for drug trials
21 CFR 812:150 (a) (FDA) reporting requirements for device trials - investigator
21 CFR 812.150 (b) (FDA) reporting rules for sponsors in device trials – sponsor
21 CFR 812.3 (FDA) Investigational Device Exemptions - definitions
21 CFR 812.46 (FDA) Investigational Device Exemptions – monitoring investigations